. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 284: H122-H132, 2003;10.1152/ajpheart.00233.2002.-The purpose of this study was to test the hypothesis that acute disruption of fibrillar collagen will decrease myocardial systolic performance without changing cardiomyocyte contractility. Isolated papillary muscles were treated either with plasmin (0.64 U/ml, 240 min) or untreated and served as same animal control. Plasmin treatment caused matrix metalloproteinase activation and collagen degradation as measured by gelatin zymography, hydroxyproline assays, and scanning electron microscopy. Plasmin caused a significant decrease in myocardial systolic performance. Isotonic shortening extent and isometric developed tension decreased from 0.17 Ϯ 0.01 muscle length (ML) and 45 Ϯ 4 mN/mm 2 in untreated muscles to 0.09 Ϯ 0.01 ML and 36 Ϯ 3 mN/mm 2 in treated muscles (P Ͻ 0.05). However, plasmin treatment (0.64 U/ml, 240 min) did not alter shortening extent or velocity in isolated cardiomyocytes. Acute disruption of the fibrillar collagen network caused a decrease in myocardial systolic performance without changing cardiomyocyte contractility. These data support the hypothesis that fibrillar collagen facilitates transduction of cardiomyocyte contraction into myocardial force development and helps to maintain normal myocardial systolic performance. hypertrophy; matrix metalloproteinases; heart failure; muscle; plasmin MANY AUTHORS (3, 17, 25, 35) have hypothesized that the extracellular matrix (ECM) fibrillar collagen network facilitates transduction of cardiomyocyte contraction into myocardial force development and shortening and that changes in collagen may also alter myocardial systolic performance. The basis for this hypothesis is partly because pathological states, which result in the development of systolic dysfunction and congestive heart failure, are associated with significant changes in fibrillar collagen (8, 11, 13, 29, 34, 36, 37) . However, these same pathological processes simultaneously change several other cellular and extracellular factors, which can also play a causal role in the development of systolic dysfunction and congestive heart failure (1). In addition, the specificity with which a decrease in collagen can be linked causally to a decrease in systolic function is uncertain because some pathological processes that increase collagen as well as some that decrease collagen can result in systolic dysfunction (8, 11, 13, 29, 34, 36, 37) .
hypertrophy; matrix metalloproteinases; heart failure; muscle; plasmin MANY AUTHORS (3, 17, 25, 35) have hypothesized that the extracellular matrix (ECM) fibrillar collagen network facilitates transduction of cardiomyocyte contraction into myocardial force development and shortening and that changes in collagen may also alter myocardial systolic performance. The basis for this hypothesis is partly because pathological states, which result in the development of systolic dysfunction and congestive heart failure, are associated with significant changes in fibrillar collagen (8, 11, 13, 29, 34, 36, 37) . However, these same pathological processes simultaneously change several other cellular and extracellular factors, which can also play a causal role in the development of systolic dysfunction and congestive heart failure (1) . In addition, the specificity with which a decrease in collagen can be linked causally to a decrease in systolic function is uncertain because some pathological processes that increase collagen as well as some that decrease collagen can result in systolic dysfunction (8, 11, 13, 29, 34, 36, 37) .
Therefore, it is not intuitively obvious whether and to what extent changes in ECM myocardial fibrillar collagen can alter systolic function or contribute to the development of congestive heart failure in pathological states. Determining whether collagen degradation plays a mechanistic role in altering systolic function requires an experiment designed to cause an acute, isolated change in collagen without significantly changing any of the cellular determinants of systolic function. Accordingly, the purpose of this study was to produce an acute, isolated increase in collagen degradation without changing any cellular determinants, measure the resultant effect on myocardial systolic performance, and thereby test the hypothesis that the ECM fibrillar collagen network facilitates transduction of cardiomyocyte contraction into myocardial force development and shortening and helps to maintain normal myocardial systolic performance.
METHODS
Experimental model. Ventricular papillary muscles were isolated from six normal rats, eight normal cats, and eight cats with chronic right ventricular pressure overload hypertrophy (POH) induced by pulmonary artery banding for 4 wk. Initial pilot studies were performed in rats to establish protocol parameters. Protocols were then applied to normal and POH cats. POH was induced by partially occluding the pulmonary artery with a 2.9 mm ID band, with the use of previously described methods (41) . Eight cats underwent pulmonary artery banding and then recovered for 4 wk. Four normal adult cats and four sham-operated cats served as controls. Four weeks after pulmonary artery banding or sham operation, catheterization was performed with the use of previously described methods (41) . The effects of pulmonary artery banding on in vivo measurements of pressure, oximetry, and mass were similar to those in our previous studies (41) , in that pulmonary artery banding caused significant increases in right ventricular systolic pressure and mass. After these hemodynamic studies were completed, left ventricular papillary muscles were isolated from normal rats, and right ventricular papillary muscles were isolated from cats using previously described methods (41) . Once isolated, the papillary muscles underwent experimental treatment protocols.
All animals received humane care in compliance with the National Society for Medical Research's "Principles of Laboratory Animal Care" and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, Revised 1996) .
Experimental treatment protocols. First, the isolated muscles were immediately placed in a 50-ml container and superfused with the "experimental treatment buffer," which consisted of the cardioplegia solution, as described previously (41) , with either plasmin (plasmin-treated group) or without plasmin (untreated control group) for 240 min. Plasmin is a serine protease that activates endogenous matrix metalloproteinases (MMPs). Activated MMPs have the ability to cleave specific ECM proteins, including fibrillar collagen. Paired muscles were randomly assigned to the untreated control protocol versus the plasmin-treated protocol. The plasmin-treated group was superfused with the experimental treatment buffer containing 0.64 U/ml concentration of plasmin. Initial studies to determine optimal plasmin concentration and length of treatment with plasmin were performed in normal rats. Dose and time titration studies were done from 0.16-0.64 U/ml and from 0 to 240 min. These studies showed that the amount of hydroxyproline liberated into the bath reached a plateau at a plasmin dose of 0.64 U/ml for 240 min. In addition, these dose and time ranges resulted in a significant effect in myocardial systolic performance in normal muscles. After plasmin treatment, the muscle was placed in the isolated muscle chamber and subjected to the mechanical testing protocol described below. Untreated control muscles were treated in a fashion identical to that described above, except that the experimental treatment buffer did not contain plasmin.
Second, after a 240-min treatment, the muscles were removed from the experimental treatment buffer and placed in an isolated muscle study chamber and superfused with Krebs-Henseleit "mechanical testing buffer" consisting of (in mM) 98.0 NaCl, 4.7 KCl, 1.2 MgSO 4, 1.1 KH2PO4, 24.0 NaHCO3, 20.0 NaAc, 2.5 CaCl2, 11.2 glucose, and 10 U/l insulin but without plasmin (95% O2-5% CO2, pH 7.38, 29°C) to undergo mechanical testing to characterize myocardial systolic performance.
Papillary muscle servo control system. A computer-controlled dual-mode (length and force) servo system was used to mechanically test the papillary muscles. Studies examining the effects of treatment with plasmin on myocardial diastolic viscoelastic properties from these same papillary muscles are the subject of a separate report. This study examined the effects of treatment with plasmin in normal and POH on myocardial systolic performance. The characteristics of the servo control system, the preconditioning protocol, and the methods used to measure muscle length (ML) and crosssectional area, have been described in detail (41) . Myocardial systolic performance was examined in ventricular papillary muscles by measuring the following: extent and velocity of isotonic shortening, extent and rate of isometric force development, and the developed tension versus resting ML relationship. Length was expressed as a percentage of the rest length at maximum length (Lmax) ML and force was normalized by muscle cross-sectional area (mN/mm 2 ). Maximum isotonic shortening extent and velocity (ϪdL/dt) were measured as ML and ML/s, respectively. Maximum isometric developed tension and the rate of tension development (ϩdT/ dt) were measured as mN/mm 2 and mN ⅐ mm 2 ⅐ s Ϫ1 , respectively. The developed tension versus resting ML relationship was derived from the L max determinations in each muscle.
MMP activation. In a subset of studies (n ϭ 3), the experimental treatment buffer from the untreated control and the plasmin-treated muscles were rapidly decanted and flash frozen. These samples were subjected to substrate-specific MMP zymographic analysis, as described previously (21, 27, 32) . The buffer was initially lyophilized and then reconstituted in zymographic buffer solution. Purified MMP-9 and MMP-2 standards (CalBiochem; La Jolla, CA) were included in all zymograms. After electrophoresis and incubation, the zymograms were stained and digitally quantitated by image analysis (Gel Pro Analyzer, Media Cybernetics) (21, 27, 32) .
Hydroxyproline assay. Collagen degradation was quantified by measuring the amount of hydroxyproline present in the experimental treatment buffer of both untreated control and plasmin-treated normal rat papillary muscles. Hydroxyproline concentration was determined by using a modified method of Stegemann and Stalder (30) . Hydroxyproline standard solutions were made, and a standard curve was obtained. Two milliliters of the experimental treatment buffer were lyophilized, resuspended with the assay buffer, and mixed with 500 ml of chloramine-T reagent. An aldehyde-perchloric acid solution was added, the samples were immersed in a 60°C bath for 15 min, and then cooled in tap water. The absorbency of the samples was obtained, and the hydroxyproline concentration was assessed using the curve obtained from the standard solutions.
ECM characterization scanning and transmission electron microscopy. Fibrillar collagen distribution and geometry were characterized using scanning electron microscopy (EM), as previously described (14, 28, 29) . After measurements of systolic performance were completed, muscles were held at a constant length equal to the length at Lmax. The mechanical testing buffer was then removed and replaced by 2.5% gluteraldehyde fixative for 3 h. The myocardial samples were critical point dried and then freeze fractured. The freezefractured samples were dehydrated and gold sputter coated (Hummer II; Technics). The sections were examined with a JEOL JSM-25S scanning electron microscope at an accelerating voltage of 15 kV. Myocardial samples were prepared in triplicate and at least 10 photomicrographs of the extracellular space were obtained from each sample. Additional muscle sections were prepared for EM as described previously (29) . Briefly, thin myocardial sections were prepared from each papillary muscle, stained with uranyl acetate and lead citrate, and examined with a JEOL JEM-1210 electron microscope. The central portion of each section was digitized at a precalibrated magnification.
Measurements of cardiomyocyte systolic performance. In a subset of studies (n ϭ 4 normal cats), cardiomyocyte systolic performance was examined by measuring the extent and velocity of isotonic cell and sarcomere shortening. Cardiomyocytes were isolated from feline myocardium with the use of previously described methods (18) . Cardiomyocytes were divided into two aliquots; one was treated with plasmin (KrebsHenseleit buffer with plasmin, 0.64 U/ml for 240 min) and the second was the untreated control (Krebs-Henseleit buffer without plasmin for 240 min). A minimum of 15 cells from each of the two aliquots from each of four isolations was studied (n ϭ 60 cells/group). The cells were placed in a custom-designed study chamber, superfused with KrebsHenseleit buffer, including 2.5 mM calcium, maintained at pH 7.4, 37°C, and electrically stimulated to contract at 1 Hz. Cardiomyocyte and sarcomere length and velocity transients were determined using computer assisted videomicroscopy and computer controlled video edge-detection protocols (IonOptix; Milton, MA). The experimental apparatus used in this study did not allow examinations of isometric contractions in isolated cardiomyocytes and did not allow isolated cardiomyocytes to undergo isotonic contractions at L max preloaded length. Therefore, the mechanical studies performed in isolated cardiomyocytes do not precisely correspond to the studies performed in isolated papillary muscles. However, they were sufficient to determine the effects of plasmin on cardiocyte contractile state.
Statistics. Data are presented as means Ϯ SE for each data group. Differences between normal and POH groups at baseline and after plasmin treatment were determined with multiple analysis of variance and a Newman-Keuls multiplesample comparison test and were considered significant at P Ͻ 0.05.
RESULTS

Effects of plasmin on MMP activation and collagen degradation.
Representative zymograms from the experimental treatment buffer from untreated control and plasmin-treated muscles were analyzed (Fig. 1) . In the untreated controls, there was no detectable zymographic activity in the buffer. This absence of MMP zymographic activity suggested that MMPs were not spontaneously activated and released into the buffer during this treatment period. In marked contrast, however, MMP zymographic activity contained within the 50-90 kDa region, consistent with proteolytic activity for MMP-9 and MMP-2, respectively (38), was significantly increased with plasmin treatment. These results indicated that treatment with the serine protease plasmin caused MMP activation and release into the Scanning electron microscopy (EM) was performed on papillary muscle samples, which had been fixed at maximum length (Lmax) preload. In normal myocardium (top left), a fine fibrillar collagen weave was observed within the interstitium. In normal myocardium after treatment with plasmin (top right), significant loss of the fibrillar collagen weave could be readily detected in all samples examined. In POH muscles (bottom left), a significantly thickened collagen weave surrounded individual myocytes and a robust fascicular collagen matrix was observed throughout the sections examined. In POH muscles after plasmin treatment (bottom right), noticeable defects in the thick collagen fascicular weave were readily apparent.
experimental treatment buffer superfusing the muscle. Moreover, there appeared to be a greater degree of MMP zymographic activity contained within the experimental treatment buffer from plasmin-treated muscles from the POH muscle samples compared with the normal muscles treated with plasmin. Densitometric analysis of the proteolytic region spanning from 50-90 kDa revealed a greater lytic region contained within the POH samples compared with normal samples (1, (Fig. 2) . Plasmin-treated muscles exhibited a defect in the collagen fascicular weave that surrounds cardiac myocyte bundles, but there were no gross defects in the sarcolemmal membrane or other architectural evidence of significant cardiomyocyte injury (Fig. 3) . However, in some areas there appeared to be a higher prevalence of adjacent myofibrils, in which poor registration of Z-bands occurred.
Effects of plasmin on myocardial systolic performance in normal muscles. The effects of plasmin treatment on the systolic performance in normal rat papillary muscles are shown in Fig. 4 . When normal rat papillary muscles were treated with plasmin, there was a significant decrease in ϪdL/dt and a significant decrease in ϩdT/dt. The effects of plasmin treatment on the systolic performance in normal cat papillary muscles are shown in Fig. 5 .
05).
Effects of plasmin on myocardial systolic performance in POH cat. The effects of plasmin treatment on systolic performance in the POH cat papillary muscles Fig. 3 . Representative transmission electron micrographs from normal muscle treated with (B) and without (A) plasmin. In untreated normal myocardium, the sarcolemma was intact and clear sarcomeric registration within individual myofibrils could be appreciated (A, top and bottom). The mitochondria revealed mild swelling, which separated the christae; there were no differences between control vs. plasmin-treated muscles. This effect was likely due to the 3-h storage of the muscle segments in a crystalloid buffering solution. In sections taken from muscle segments treated with plasmin, there were no gross defects in the sarcolemmal membrane or other architectural evidence of significant myocyte injury. However, in certain sections examined, there appeared to be a higher prevalence of adjacent myofibrils, in which poor registration of Z-bands occurred (B, top and bottom).
are shown in Fig. 6 . When POH muscles were treated with plasmin, there was a significant decrease in ϪdL/dt from 0.08 Ϯ 0.01 ML and 0.34 Ϯ 0.03 ML/s to 0.04 Ϯ 0.2 ML and 0.21 Ϯ 0.04 ML/s (P Ͻ 0.05), and in ϩdT/dt from 20 Ϯ 2 mN/mm 2 and 94 Ϯ 11 mN ⅐ mm 2 ⅐ s Ϫ1 to 13 Ϯ 4 mN/mm 2 and 65 Ϯ 14 mN ⅐ mm 2 ⅐ s Ϫ1 (P Ͻ 0.05). Effects of POH and plasmin on developed tension versus length relationship. POH caused a shift downward of the developed tension versus resting ML relationship such that for any given rest length, developed tension was less in the POH muscles (Fig. 7) . In normal rat, normal cat, and POH cat muscles, plasmin treatment caused a downward shift in this relationship, indicating that plasmin decreased myocardial systolic performance.
Effects of plasmin on systolic performance of normal cat cardiomyocytes. The effects of plasmin treatment on the systolic performance in normal cat cardiomyocytes are shown in Fig. 8 . Plasmin treatment did not alter the cardiomyocyte or sarcomere ϪdL/dt.
DISCUSSION
The major findings of this study include the following: 1) treatment of isolated papillary muscles from normal and POH cats with serine protease plasmin caused activation of MMPs and collagen degradation; 2) myocardial force development and shortening were significantly decreased after treatment with plasmin; however, 3) plasmin treatment did not alter cardiomyocyte shortening. Thus acute disruption of the fibrillar collagen network caused a decrease in myocardial systolic performance without changing cardiomyocyte contractility. Therefore, these data support the hypothesis that fibrillar collagen facilitates transduction of cardiomyocyte contraction into myocardial force develop- Fig. 4 . Effects of plasmin treatment on normal rat myocardial systolic performance. A: example of myocardial shortening of an untreated control (solid trace) and of a plasmin-treated (dashed trace) papillary muscle from a normal rat. B and C: group data from treated and untreated normal rat papillary muscles. Plasmin treatment significantly decreased shortening extent and velocity. D: example of myocardial tension development of an untreated control and of a plasmin-treated papillary muscle from a normal rat. E and F: group data from treated and untreated normal rat papillary muscles. Plasmin treatment significantly decreased developed tension and the rate of tension development (ϩdT/dt). ML, muscle length. ment and helps to maintain normal myocardial systolic performance.
There are at least two possible mechanisms by which fibrillar collagen might facilitate transduction of cardiomyocyte contraction into normal myocardial contractility. First, myocardial fibrillar collagen forms a complex three-dimensional matrix, which surrounds, invests, and connects individual cardiomyocytes and groups of cardiomyocytes (fascicles). Fibrillar collagen may help to maintain cardiac muscle structural organization, which consists of geometrically positioned cardiomyocyte fascicles. Within the muscle, cardiomyocyte fascicles act in a coordinated and homogeneous fashion to produce efficient contraction. Degradation of the fibrillar collagen matrix, such as occurs with MMP activation, may result in discontinuities in the collagen matrix and disruption of the matrix-mediated support, geometric alignment, and coordination of adjacent cardiomyocyte fascicle contraction. Therefore, one mechanism that might cause the reduction of force development and shortening observed in the present study after treatment with the serine protease plasmin was a loss of optimal geometric alignment and coordination of cardiomyocyte fascicles within the papillary muscle.
A second mechanism might involve the loss of the normal collagen matrix-basement membrane-integrin relationship. Collagen attaches to basement membrane proteins, which in turn form connections to integrin-mediated focal adhesion complexes at the surface of cardiomyocytes. These connections occur predominantly at the sarcomeric Z-line and the cardiomyocyte intercalated disks. Endomysial collagen struts form lateral connections between cardiomyocytes. These collagen connections are thought to contribute to the processes holding sarcomeres in registry at equal end diastolic lengths across myofibrils at the start of contraction. This creates equally preloaded sarcomeres across myofibrils. In addition, these collagen connections are thought to contribute to the processes keeping sarcomeres in registry throughout contraction, creating a homogeneous contraction. Furthermore, disruption of this sarcomeric registration might lead to a nonhomogeneous contraction creating both asynchrony and asynergy, which, in turn, result in a decrease in contractile state. Data from the present study support this notion. In plasmin-treated muscles, the reduction in contractility was associated with some alterations in the normal sarcomeric Z-band registry.
Chronic changes in fibrillar collagen. Several studies have attempted to define the relationship between changes in ECM fibrillar collagen and myocardial systolic performance. Disease states such as POH, dilated cardiomyopathy, and myocardial infarction cause decreases in systolic function, which have been associated with a decrease, an increase, or no change in fibrillar collagen. This variability makes it difficult to assign a causal relationship between changes in collagen and the development of systolic dysfunction.
For example, in dilated cardiomyopathy or myocardial infarction, increased MMP expression and abundance and increased degradation of ECM fibrillar collagen occur early in the course of the disease simultaneously with a decrease in systolic performance and the development of congestive heart failure (11, 17, 27, 29, 32, 37) . When MMPs are pharmacologically inhibited in animal models of dilated cardiomyopathy, there is less degradation of collagen, less myocardial remodeling, and systolic function is at least partially preserved (9, 20, 22, 23, 26, 28) . Anand and colleagues (7, 12, 24) , by using a coronary ligation model of myocardial infarction in a rodent, showed that whereas indexes of myocardial systolic performance were reduced, cardiomyocytes isolated from residual, noninfarcted myocardium had normal contractile performance. This disparity between myocardial and cardiomyocyte function occurred in the presence of significant degradation of collagen and significant decreases in the fibrillar collagen network. These investigators suggest that this collagen degradation played a causal role in the loss of systolic performance after myocardial infarction. In contrast to dilated cardiomy- Fig. 6 . Effects of plasmin treatment on POH cat myocardial systolic performance. A: example of myocardial shortening of an untreated control (solid trace) and of a plasmin-treated (dashed trace) papillary muscle from a POH cat. B and C: group data from treated and untreated POH cat papillary muscles. Plasmin treatment significantly decreased shortening extent and velocity. D: example of myocardial tension development of an untreated control and of a plasmin-treated papillary muscle from a POH cat. E and F: group data from treated and untreated POH cat papillary muscles. Plasmin treatment significantly decreased ϩdT/dt. opathy and myocardial infarction, POH is associated with decreased MMP expression and abundance, decreased collagen degradation, increased collagen accumulation, but eventually a decrease in systolic performance and the development of congestive heart failure (2, 4, 5, 8, 10, 13, 15, 19, 21, 34, 36, 39) . Thus these studies in POH, dilated cardiomyopathy, and myocardial infarction do not provide a unified conclusion relating collagen metabolism to myocardial systolic performance. It should be remembered, however, that interpretation of each of these chronic studies was complicated by the fact that each pathological state caused simultaneous changes in many determinants of systolic performance, which made assigning specificity to a change in collagen problematic. These studies emphasize the importance of the present study, in which an acute isolated increase in collagen degradation was produced without changing other functional determinants.
Acute changes in fibrillar collagen. Previous experimental approaches (6, 16, 31, 33, 40) attempted to accomplish the goal of an acute increase in collagen degradation using methods such as acute ischemia, treatment with disulfide reagents, or treatment with exogenous collagenase. The results of these studies have been difficult to interpret because the results were not consistent and because many determinants of systolic performance, including intracellular mechanisms affecting energetics and calcium metabolism and extracellular mechanisms affecting myocardial edema, were altered simultaneously.
An alternate approach to producing an acute and isolated increase in collagen degradation would be to activate a protease system normally present within the myocardium, such as MMPs. The MMPs constitute a family of zinc-dependent enzymes, which contribute to changes in ECM structure and composition in both normal and abnormal tissue remodeling. It is now clear that myocardial MMPs can contribute to changes in ECM structure in cardiac disease states such as myocardial infarction and dilated cardiomyopathy. However, studies that provide a direct mechanistic link between changes in MMP expression and/or activity with structural and functional properties of the cardiac muscle itself have been limited. In the present study, the experimental treatment buffer from untreated muscle contained no MMP gelatinolytic activity. This observation was expected because MMPs are synthesized, released in a proenzyme form, and remain bound to the ECM in an inactive state. In vitro studies have demonstrated that MMPs are activated through proteolytic cleavage of the propeptide domain, which can be achieved by serine proteases such as plasmin or trypsin. In the present study, treating papillary muscle with plasmin resulted in alterations in MMP gelatinolytic activity within the experimental treatment buffer solution. The proform of MMP-2 is 72 kDa, and the active form is ϳ68 kDa. The gelatin zymography revealed robust proteolytic activity at ϳ68 kDa in the experimental treatment buffer following treatment with plasmin, which would indicate the activation and release of MMP-2. Previous studies have demonstrated that abundant quantities of MMP-2 exist within normal and hypertrophied myocardium. In contrast, MMP-9 is expressed to a lesser degree in normal myocardium and increases only in cardiac disease states. Thus, in the present study, the limited proteolytic activity corresponding to MMP-9 likely reflects a limited endogenous pool of this MMP species contained within these myocardial samples. However, it must be recognized that gelatin zymography is optimized to detect MMP-2 and MMP-9, and therefore the activation and release of other MMPs after plasmin treatment would not be detected by this approach. The hydroxyproline results provide evidence that other MMPs were activated by plasmin treatment. Hydroxyproline is uniquely contained within collagen, and the fibrillar collagen types I and III constitute an important set of structural proteins within the myocardial ECM. The primary MMPs responsible for fibrillar collagen degradation are the interstitial collagenases MMP-1 and MMP-13; both of which have been identified in normal and pathological myocardium. Thus it is likely that a cascade of MMP activation and subsequent ECM degradation occurred when these isolated papillary muscle preparations were treated with plasmin.
POH. The present study used normal and POH muscle preparations to examine specific determinants of cardiac muscle function after plasmin treatment and putative MMP activation. A complete quantification of the POH muscle preparations was beyond the scope of this report. The characteristics of this POH preparation and the alterations in cellular and ECM structure have been described previously. However, two observations were made about changes in the ECM and MMPs in these POH muscles, which warrant further comment. First, the scanning electron micrographs revealed a thickened fibrillar collagen weave in the POH muscles, which is consistent with this form of hypertrophy. Second, a more robust gelatinolytic activity was realized in POH muscles after plasmin treatment. This likely reflects a greater quantity of recruitable MMPs in the POH myocardium. Whereas the increased collagen accumulation and MMP abundance in the POH myocardium may appear paradoxical, there are several regulatory processes that contribute to MMP activational states. First, MMPs are synthesized in an inactive state and require an exogenous biochemical trigger or physical stimulus to yield a fully active MMP. Second, a set of regulatory proteins, tissue inhibitors of MMPs (TIMPs), exists within the myocardium that rapidly and tightly binds to active MMPs and interrupt proteolytic activity. The induction of a pressure overload has been demonstrated to cause a shift in the stoichiometry between MMPs and TIMPs, which would favor reduced MMP proteolytic activity and collagen accumulation. The results of the present study demonstrated that a significant amount of recruitable MMPs exist within the ECM of the POH myocardium. Future studies that more fully determine the relative abundance and MMP species, which exist within the POH myocardium, are warranted.
Components of ECM.
There are other components of ECM that may also contribute to the maintenance of systolic function. In addition to fibrillar collagen, the myocardial ECM is composed of the following: 1) other fibrillar protein such as elastin; 2) proteoglycans; and 3) basement membrane proteins, such as collagen type IV, laminin, and fibronectin. There is no clear evidence that proteins other than fibrillar collagen change during clinical pathological processes or what role these changes would have. Nonetheless, this may have relevance to the present study because plasmin does not act directly on fibrillar collagen; rather, plasmin degrades collagen indirectly by activating a cascade of MMPs, which in turn can degrade collagen. This cas- cade may also activate MMPs, whose specific protein targets include other proteins within the ECM in addition to fibrillar collagen. To prove what role each MMP species and each MMP target protein contributes to change in systolic performance will require additional studies. This kind of specificity may be possible either by treatment with selective recombinant MMPs or by the addition of selective MMP inhibitors to the plasmin treatment. However, the first step in such experimental designs was taken in the current study, providing proof of concept activation of endogenous MMPs and degradation of collagen resulted in a decrease in myocardial systolic performance.
